Takeda's dengue vaccine wins EU approval




  • In US
  • 2022-12-08 12:01:08Z
  • By Reuters
 

By Natalie Grover

LONDON (Reuters) -Japanese company Takeda's dengue vaccine was authorised for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.

The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue.

There are no antivirals or specific treatments for the flu-like viral disease. While the illness is mostly mild, some people can develop life-threatening complications. Between 20,000 to 25,000 people, mostly children, die each year, according to the World Health Organization.

QDENGA follows Sanofi's Dengvaxia, which was the world's first dengue vaccine and which secured its first approval in 2015.

The use of the French drugmaker's vaccine was scaled back considerably after the company disclosed in 2017 that it increased the risk of severe disease in 'seronegative' children - those who had no prior dengue exposure when they got the shot

Takeda's vaccine is based on a dengue 2 virus, with DNA from the other three serotypes added in. Data from a pivotal trial has shown the vaccine can induce immune responses to a varied degree against all four dengue types.

Compared to Dengvaxia, Takeda's vaccine shows wider protection for young children and people older than 45 years old, EU health regulators said in October when they recommended authorising QDENGA.

The Takeda vaccine has also been approved in Indonesia, while US regulators are reviewing QDENGA on a priority basis.

Takeda expects its vaccine to generate $700 million to $1.6 billion in sales over the course of several years, Gary Dubin, president of Takeda's global vaccine business, told Reuters earlier this year.

(Reporting by Natalie Grover in LondonEditing by Jason Neely and Frances Kerry)

COMMENTS

More Related News

Italy
Italy's premier visits Libya for talks on energy, migration
  • US
  • 2023-01-28 10:23:45Z

Italy's prime minister visited Libya for talks Saturday with officials from the country's west-based government focusing on energy and migration, top issues ...

The EU just approved insects for human consumption with plenty of
The EU just approved insects for human consumption with plenty of 'environmental benefits' - are mealworms the low-cost, sustainable answer to soaring meat prices?

Cricket casserole, anyone?

ICE to open London gas hub, creating route around EU price cap
ICE to open London gas hub, creating route around EU price cap

The Intercontinental Exchange plans to launch a "parallel market" in London for Title Transfer Facility gas trading next month, it said on Friday, providing ...

Yellen to meet with donors, private sector on South Africa
Yellen to meet with donors, private sector on South Africa's energy transition

U.S. Treasury Secretary Janet Yellen met with local officials in South Africa's coal mining region of Mpumalanga on Friday, pledging America's firm support...

Sanofi
Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval
  • US
  • 2023-01-27 06:37:50Z

Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for their Dupixent...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US